Krishna Institute of Medical Sciences Ltd filed its audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The filing confirms that the company maintained adequate internal financial controls over financial reporting during the period. The results, approved by the Board of Directors on May 15, 2026, are subject to adoption by shareholders at the ensuing Annual General Meeting.

The Statutory Auditors, S.R. Batliboi & Associates LLP, issued an audit report dated May 15, 2026. The report confirms that the company used accounting software with an audit trail feature that operated throughout the year for all relevant transactions. The auditors stated they did not encounter any instance of the audit trail feature being tampered with during the course of the audit.

Regarding the consolidated financial statements, the auditors reported that the group and its associate companies, incorporated in India, maintained adequate internal financial controls. These controls were operating effectively as at March 31, 2026, based on criteria established by the company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

The auditors also addressed other legal and regulatory requirements in their report. They confirmed that the company did not incur cash losses in the current financial year or in the immediately preceding financial year. Furthermore, there was no resignation of the statutory auditors during the year.

The company stated that no dividend was declared or paid during the year by the holding company, its subsidiaries, or the associate company incorporated in India. The audit trail of prior years has been preserved by the company as per statutory requirements for record retention to the extent it was enabled and recorded in the respective year.

Krishna Institute of Medical Sciences Ltd disclosed that its promoter group has not created any new encumbrances on shares during the financial year ending March 31, 2026. The declaration was submitted by Dr. Bhaskara Rao Bollineni, Chairman and Managing Director, on behalf of the promoter and promoter group pursuant to Regulation 31(4) read with Regulation 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The filing confirms that aside from previously disclosed pledges, no shares were encumbered directly or indirectly by the promoters during the period. The disclosure provides transparency regarding the holding patterns of key stakeholders in the hospital chain.

Shareholding and Pledge Details

The total promoter and promoter group holding amounts to 13,64,89,330 shares, representing 34.11% of the company. Out of this, a total of 1,40,00,000 shares are pledged, accounting for 3.50% of the total shareholding. All pledged shares belong to Dr. Bhaskara Rao Bollineni.

Dr. Bhaskara Rao Bollineni holds the largest stake within the promoter group at 10,50,99,645 shares, constituting 26.27% of the total equity. Other members of the promoter group, including Rajyasri Bollineni and Bluebridge Capital Private Limited, hold significant stakes but have not pledged any of their holdings.